Shopping Cart 0
Cart Subtotal
USD 0

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2018, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 1, 1, 24, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).

- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Chemotherapy Induced Peripheral Neuropathy-Overview 6

Chemotherapy Induced Peripheral Neuropathy-Therapeutics Development 7

Chemotherapy Induced Peripheral Neuropathy-Therapeutics Assessment 15

Chemotherapy Induced Peripheral Neuropathy-Companies Involved in Therapeutics Development 23

Chemotherapy Induced Peripheral Neuropathy-Drug Profiles 32

Chemotherapy Induced Peripheral Neuropathy-Dormant Projects 123

Chemotherapy Induced Peripheral Neuropathy-Discontinued Products 125

Chemotherapy Induced Peripheral Neuropathy-Product Development Milestones 126

Appendix 136


List Of Figure

List of Figures

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Achelios Therapeutics Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Aptinyx Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Asahi Kasei Corp, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Can-Fite BioPharma Ltd, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Celgene Corp, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Immune Pharmaceuticals Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Insys Therapeutics Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Kineta Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Mundipharma International Ltd, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Nemus Bioscience Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Neurocentrx Pharma Ltd, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by PeriphaGen Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by PledPharma AB, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Sensei Biotherapeutics Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Sova Pharmaceuticals Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Trevena Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Pipeline by WEX Pharmaceuticals Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Dormant Projects, H2 2018

Chemotherapy Induced Peripheral Neuropathy-Dormant Projects, H2 2018 (Contd..1), H2 2018

Chemotherapy Induced Peripheral Neuropathy-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Chemotherapy Induced Peripheral Neuropathy Therapeutic Products under Development, Key Players in Chemotherapy Induced Peripheral Neuropathy Therapeutics, Chemotherapy Induced Peripheral Neuropathy Pipeline Overview, Chemotherapy Induced Peripheral Neuropathy Pipeline, Chemotherapy Induced Peripheral Neuropathy Pipeline Assessment


Companies

Achelios Therapeutics Inc

Aptinyx Inc

Asahi Kasei Corp

Can-Fite BioPharma Ltd

Celgene Corp

Immune Pharmaceuticals Inc

Insys Therapeutics Inc

Kineta Inc

Kyorin Pharmaceutical Co Ltd

Mundipharma International Ltd

Nemus Bioscience Inc

Neurocentrx Pharma Ltd

PeriphaGen Inc

PledPharma AB

Sensei Biotherapeutics Inc

Sova Pharmaceuticals Inc

Trevena Inc

WEX Pharmaceuticals Inc